Taro gets bad news
This article was originally published in The Tan Sheet
Executive Summary
Two class action suits allege Securities Exchange Act violations by generics firm Taro Pharmaceutical Industries. Suits say the company failed to disclose "adverse factors that were having a negative impact on Taro's financial performance" such as the "increased competitive pressures" the firm was experiencing in the generic drugs business. Philadelphia-based law firm Berger & Montague and New York-based firm Abbey Gardy allege that Taro disregarded hefty costs to develop its branded Rx drug business. Both complaints are filed on behalf of all Taro securities purchasers from Feb. 20 2003 to July 29, 2004...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.